CN103687595B - 作为二酰基甘油酰基转移酶抑制剂的新化合物 - Google Patents
作为二酰基甘油酰基转移酶抑制剂的新化合物 Download PDFInfo
- Publication number
- CN103687595B CN103687595B CN201280035285.1A CN201280035285A CN103687595B CN 103687595 B CN103687595 B CN 103687595B CN 201280035285 A CN201280035285 A CN 201280035285A CN 103687595 B CN103687595 B CN 103687595B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- amino
- acetic acid
- carbamoyl
- bases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **=*CC(NC(N*)=O)=* Chemical compound **=*CC(NC(N*)=O)=* 0.000 description 35
- DKUAUHFLWURXHI-UHFFFAOYSA-N CC(CC(O)=O)(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(C(F)(F)F)c2)=O)ccc11)C1=O Chemical compound CC(CC(O)=O)(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(C(F)(F)F)c2)=O)ccc11)C1=O DKUAUHFLWURXHI-UHFFFAOYSA-N 0.000 description 1
- GRGFEXYZIUXPSQ-UHFFFAOYSA-N CCC(CC(OCC)=O)(Cc1cc(Br)ccc11)C1=[U] Chemical compound CCC(CC(OCC)=O)(Cc1cc(Br)ccc11)C1=[U] GRGFEXYZIUXPSQ-UHFFFAOYSA-N 0.000 description 1
- HRQLYASVIBPADF-UHFFFAOYSA-N CCOC(CC(CC(F)(F)F)(C=Cc1cc(-c(cc2)ccc2NC(Nc2ccccc2)=O)ccc11)C1=O)=O Chemical compound CCOC(CC(CC(F)(F)F)(C=Cc1cc(-c(cc2)ccc2NC(Nc2ccccc2)=O)ccc11)C1=O)=O HRQLYASVIBPADF-UHFFFAOYSA-N 0.000 description 1
- FKIMQTVTQJHXBP-UHFFFAOYSA-N CCOC(CC(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(C(F)(F)F)c2)=O)ccc11)(C1=O)O)=O Chemical compound CCOC(CC(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(C(F)(F)F)c2)=O)ccc11)(C1=O)O)=O FKIMQTVTQJHXBP-UHFFFAOYSA-N 0.000 description 1
- PJDOPQGXUSATNI-UHFFFAOYSA-N CCOC(CCC(CCc1cc(-c(cc2)ccc2[N+]([O-])=O)ccc11)C1O)=O Chemical compound CCOC(CCC(CCc1cc(-c(cc2)ccc2[N+]([O-])=O)ccc11)C1O)=O PJDOPQGXUSATNI-UHFFFAOYSA-N 0.000 description 1
- MPPRLORBTDXCPI-UHFFFAOYSA-N Cc(cc1)ccc1-c1ccc(C(C(CC2)O)(OC)OC)c2c1 Chemical compound Cc(cc1)ccc1-c1ccc(C(C(CC2)O)(OC)OC)c2c1 MPPRLORBTDXCPI-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N Nc1cccc(C(F)(F)F)c1 Chemical compound Nc1cccc(C(F)(F)F)c1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- MQWZSSIUHXNNTM-UHFFFAOYSA-N O=C(CC1)Nc(cc2)c1cc2Br Chemical compound O=C(CC1)Nc(cc2)c1cc2Br MQWZSSIUHXNNTM-UHFFFAOYSA-N 0.000 description 1
- KSONICAHAPRCMV-UHFFFAOYSA-N O=C(CCc1c2)c1ccc2Br Chemical compound O=C(CCc1c2)c1ccc2Br KSONICAHAPRCMV-UHFFFAOYSA-N 0.000 description 1
- CLYXLIWJZWGULU-UHFFFAOYSA-N OC(CC(CCc1cc(O)ccc11)C1=O)=O Chemical compound OC(CC(CCc1cc(O)ccc11)C1=O)=O CLYXLIWJZWGULU-UHFFFAOYSA-N 0.000 description 1
- PFTRMWGVCRYJIY-UHFFFAOYSA-N OC(CC(O)=O)(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(C(F)(F)F)c2)=O)ccc11)C1=O Chemical compound OC(CC(O)=O)(CCc1cc(-c(cc2)ccc2NC(Nc2cccc(C(F)(F)F)c2)=O)ccc11)C1=O PFTRMWGVCRYJIY-UHFFFAOYSA-N 0.000 description 1
- ZNHHCASYCWWBCW-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1-c(cc1CCC2)ccc1C2=O)=O Chemical compound [O-][N+](c(cc1)ccc1-c(cc1CCC2)ccc1C2=O)=O ZNHHCASYCWWBCW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1451DE2011 | 2011-05-20 | ||
| IN1451/DEL/2011 | 2011-05-20 | ||
| US201161495049P | 2011-06-09 | 2011-06-09 | |
| US61/495,049 | 2011-06-09 | ||
| PCT/US2012/038520 WO2012162127A1 (en) | 2011-05-20 | 2012-05-18 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103687595A CN103687595A (zh) | 2014-03-26 |
| CN103687595B true CN103687595B (zh) | 2017-05-24 |
Family
ID=47217644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280035285.1A Expired - Fee Related CN103687595B (zh) | 2011-05-20 | 2012-05-18 | 作为二酰基甘油酰基转移酶抑制剂的新化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9242929B2 (https=) |
| EP (1) | EP2723332B1 (https=) |
| JP (1) | JP5893724B2 (https=) |
| KR (1) | KR20140033426A (https=) |
| CN (1) | CN103687595B (https=) |
| AU (1) | AU2012259042B2 (https=) |
| CA (1) | CA2836666A1 (https=) |
| CO (1) | CO6811853A2 (https=) |
| CR (1) | CR20130603A (https=) |
| DO (1) | DOP2013000273A (https=) |
| EA (1) | EA023239B1 (https=) |
| ES (1) | ES2572261T3 (https=) |
| IL (1) | IL229487A0 (https=) |
| MA (1) | MA35398B1 (https=) |
| MX (1) | MX2013013565A (https=) |
| PE (1) | PE20140618A1 (https=) |
| PH (1) | PH12013502403A1 (https=) |
| SG (1) | SG194976A1 (https=) |
| WO (1) | WO2012162127A1 (https=) |
| ZA (1) | ZA201308569B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013341115B2 (en) * | 2012-11-09 | 2016-07-14 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
| WO2014081995A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
| WO2022026380A1 (en) * | 2020-07-29 | 2022-02-03 | Board Of Regents, The University Of Texas System | Urea inhibitors of micro-rna |
| CN111747876B (zh) * | 2020-08-03 | 2023-05-26 | 万华化学集团股份有限公司 | 一种氧化角黄素制备虾青素的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009126861A2 (en) * | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as dgat1 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006045209A (ja) * | 2004-07-02 | 2006-02-16 | Sankyo Co Ltd | ウレア誘導体 |
| WO2006004200A1 (ja) * | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| KR20080000652A (ko) * | 2005-04-19 | 2008-01-02 | 바이엘 파마슈티칼스 코포레이션 | 아릴 알킬산 유도체 및 그의 용도 |
| EP2402320A1 (en) | 2006-03-31 | 2012-01-04 | Novartis AG | Anorectic agents |
| GB0625654D0 (en) * | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| WO2008099221A1 (en) * | 2007-02-15 | 2008-08-21 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
| JP2008255024A (ja) * | 2007-04-02 | 2008-10-23 | Banyu Pharmaceut Co Ltd | ビアリールアミン誘導体 |
| CA2790390A1 (en) | 2009-08-28 | 2011-03-03 | Daiichi Sankyo Company, Limited | Novel tetrahydroisoquinoline compounds |
| JP2011088889A (ja) * | 2009-09-24 | 2011-05-06 | Daiichi Sankyo Co Ltd | 新規テトラヒドロイソキノリン誘導体を含有する医薬 |
| BR112012016178A2 (pt) * | 2009-12-31 | 2015-10-06 | Piramal Healthcare Ltd | inibidores de diacilglicerol aciltransferase |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
-
2012
- 2012-05-18 CN CN201280035285.1A patent/CN103687595B/zh not_active Expired - Fee Related
- 2012-05-18 US US14/118,913 patent/US9242929B2/en not_active Expired - Fee Related
- 2012-05-18 CA CA 2836666 patent/CA2836666A1/en not_active Abandoned
- 2012-05-18 PH PH1/2013/502403A patent/PH12013502403A1/en unknown
- 2012-05-18 KR KR1020137033506A patent/KR20140033426A/ko not_active Withdrawn
- 2012-05-18 SG SG2013084603A patent/SG194976A1/en unknown
- 2012-05-18 AU AU2012259042A patent/AU2012259042B2/en not_active Ceased
- 2012-05-18 ES ES12789372T patent/ES2572261T3/es active Active
- 2012-05-18 PE PE2013002520A patent/PE20140618A1/es not_active Application Discontinuation
- 2012-05-18 WO PCT/US2012/038520 patent/WO2012162127A1/en not_active Ceased
- 2012-05-18 JP JP2014511574A patent/JP5893724B2/ja not_active Expired - Fee Related
- 2012-05-18 MX MX2013013565A patent/MX2013013565A/es not_active Application Discontinuation
- 2012-05-18 EA EA201391724A patent/EA023239B1/ru not_active IP Right Cessation
- 2012-05-18 EP EP12789372.5A patent/EP2723332B1/en active Active
-
2013
- 2013-11-14 ZA ZA2013/08569A patent/ZA201308569B/en unknown
- 2013-11-18 IL IL229487A patent/IL229487A0/en unknown
- 2013-11-19 CO CO13271927A patent/CO6811853A2/es active IP Right Grant
- 2013-11-20 DO DO2013000273A patent/DOP2013000273A/es unknown
- 2013-11-20 CR CR20130603A patent/CR20130603A/es unknown
- 2013-12-13 MA MA36565A patent/MA35398B1/fr unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009126861A2 (en) * | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as dgat1 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103687595A (zh) | 2014-03-26 |
| EP2723332A1 (en) | 2014-04-30 |
| EA023239B1 (ru) | 2016-05-31 |
| US9242929B2 (en) | 2016-01-26 |
| EP2723332B1 (en) | 2016-03-02 |
| ES2572261T3 (es) | 2016-05-31 |
| DOP2013000273A (es) | 2014-04-15 |
| KR20140033426A (ko) | 2014-03-18 |
| WO2012162127A1 (en) | 2012-11-29 |
| US20150307445A1 (en) | 2015-10-29 |
| PH12013502403A1 (en) | 2018-04-11 |
| CO6811853A2 (es) | 2013-12-16 |
| PE20140618A1 (es) | 2014-06-05 |
| SG194976A1 (en) | 2013-12-30 |
| JP5893724B2 (ja) | 2016-03-23 |
| JP2014525895A (ja) | 2014-10-02 |
| MA35398B1 (fr) | 2014-09-01 |
| CR20130603A (es) | 2014-09-09 |
| CA2836666A1 (en) | 2012-11-29 |
| AU2012259042A1 (en) | 2013-04-18 |
| MX2013013565A (es) | 2014-01-08 |
| ZA201308569B (en) | 2014-07-30 |
| EP2723332A4 (en) | 2014-10-15 |
| IL229487A0 (en) | 2014-01-30 |
| AU2012259042B2 (en) | 2015-06-11 |
| EA201391724A1 (ru) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI674257B (zh) | 作為ｔｒｐｍ８拮抗劑之氮雜螺衍生物 | |
| TW201835070A (zh) | 芳香烴受體(AhR)調節劑化合物 | |
| US20100179137A1 (en) | Pyridone compound | |
| JP2021500330A (ja) | Ｐａｄ阻害剤としてのイミダゾ−ピリジン化合物 | |
| TWI577677B (zh) | 作爲ｔｔｘ－ｓ阻斷劑之吡咯並吡啶酮衍生物 | |
| HK1255103A1 (zh) | 可用於治疗与kit和pdgfr相关的病症的化合物 | |
| JP7278273B2 (ja) | アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン | |
| CN103687595B (zh) | 作为二酰基甘油酰基转移酶抑制剂的新化合物 | |
| TW201625533A (zh) | Ｋｃｎｑ ２至５通道活化劑 | |
| TW202535868A (zh) | 製備用於治療疼痛之化合物及其固體形式之方法 | |
| JP7041140B2 (ja) | 置換された６員アリール又はヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤 | |
| CN104869997B (zh) | 作为二酰基甘油酰基转移酶抑制剂的新型化合物 | |
| CN114096533B (zh) | 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途 | |
| JP4762917B2 (ja) | 非ヌクレオシド逆転写酵素インヒビター | |
| JP2019520359A (ja) | ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用 | |
| WO2016063080A1 (en) | Indazole and indole derivatives as inhibitors of retinoic acid relates orphan receptor gamma (ror gamma) for the treatment of immune-related diseases | |
| CN107522641B (zh) | 联芳基脲类衍生物或其盐及其制备方法和用途 | |
| TW202229254A (zh) | 作為crhr2拮抗劑之3-羥基吲哚酮衍生物 | |
| TW201920107A (zh) | 作為ttx-s阻斷劑之雙芳氧基衍生物 | |
| TW202535867A (zh) | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 | |
| CN115215799A (zh) | 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用 | |
| TW201309626A (zh) | 含氟的氘代二苯基脲的合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170524 Termination date: 20180518 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |